Patrick J. McEnany compensation by year
CATALYST PHARMACEUTICALS Summary Compensation Table · all 2 fiscal years held| Component | FY2022 | FY2023 |
|---|---|---|
| Salary | $691,923 | $735,000 |
| Bonus | $504,000 | $661,500 |
| Stock awards | $2,795,110 | $150,004 |
| Option awards | $2,932,749 | $599,995 |
| Non-equity incentive | $0 | $0 |
| Pension and deferred compensation | $0 | $0 |
| All other | $0 | $0 |
| Total | $6,923,782 | $2,146,499 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: CATALYST PHARMACEUTICALS, INC. DEF 14A filed April 10, 2024, accession 0001193125-24-091926, and prior-year filings.
How this page was built: the CATALYST PHARMACEUTICALS, INC. filed document, accession 0001193125-24-091926. Every figure is read from that document and cited to the page and table it appears in. Filed April 10, 2024.
Insider transactions since the last proxy
52 Form 4 lines since the FY2023 proxy (filed April 10, 2024)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-07-15 | Disposition to the issuer derivative | — | 73,810 | $0.00 | 0 |
| 2026-07-15 | Disposition to the issuer derivative | — | 10,540 | $0.00 | 0 |
| 2026-07-15 | Disposition to the issuer | — | 4,171,559 | $31.50 | 0 |
| 2026-07-15 | Disposition to the issuer derivative | — | 740,000 | $0.00 | 0 |
| 2026-07-15 | Disposition to the issuer derivative | — | 400,000 | $0.00 | 0 |
| 2026-07-15 | Disposition to the issuer derivative | — | 272,000 | $0.00 | 0 |
| 2026-07-15 | Disposition to the issuer derivative | — | 3,552 | $0.00 | 0 |
| 2026-07-15 | Disposition to the issuer derivative | — | 3,534 | $0.00 | 0 |
The 8 most recent of 52 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
CATALYST PHARMACEUTICALS’s named executive officers, FY2023
as the company reported each| Named executive officer | Role | FY2023 total |
|---|---|---|
| Steven Miller | COO and CSO | $3,404,698 |
| Jeffrey Del Carmen | CCO | $2,506,066 |
| Patrick J. McEnany · this page | Former President and Chief Executive Officer | $2,146,499 |
| Preethi Sundaram | Chief Strategy Officer | $2,145,798 |
Board service
CATALYST PHARMACEUTICALS board · FY2024–FY2025| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $193,813 | $600,014 | — | — | $793,827 |
| FY2024 | $282,211 | $562,548 | — | — | $844,759 |
Each year as the company reported it in CATALYST PHARMACEUTICALS's director compensation table. Totals are the company's own disclosed totals.
How this board is paid
Company policy: CATALYST PHARMACEUTICALS pays directors a $60,000 cash retainer and $300,019 in Stock options and RSUs. As stated in CATALYST PHARMACEUTICALS's FY2024 proxy.
The full CATALYST PHARMACEUTICALS compensation record
free company briefThis page is one person within CATALYST PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the CATALYST PHARMACEUTICALS proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are CATALYST PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.